Atropisomeric 4-phenyl-4H-1,2,4-triazoles as selective glycine transporter 1 inhibitors.

We report on the optimization of 4H-1,2,4-triazole derivatives to increase their activity and selectivity as glycine transporter 1 (GlyT1) inhibitors. Structure-activity relationship exploration resulted in the identification of a 3-[3-ethyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2-methylbenzonitrile (14u) compound with markedly higher selectivity for GlyT1. Physiochemical studies revealed that 14u exists as a stable pair of atropisomers under physiological conditions. We successfully separated the atropisomers to obtain active enantiomer (R)-14u, which displayed favorable pharmacokinetic properties, as well as positive results in the mice Y-maze test.

[1]  A. Kohara,et al.  Synthesis and biological evaluation of 3-biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as novel glycine transporter 1 inhibitors. , 2011, Journal of medicinal chemistry.

[2]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[3]  G. Lynch,et al.  Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5 , 1986, Nature.

[4]  C. Lindsley,et al.  Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. , 2008, Current opinion in molecular therapeutics.

[5]  A. Blokland,et al.  The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP Levels in hippocampal slices , 2005, Behavioural Brain Research.

[6]  M. Ōki.  Recent Advances in Atropisomerism , 2007 .

[7]  W. Turski,et al.  Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks , 1990, Neuropharmacology.

[8]  B. Kee,et al.  Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site , 2007, European Archives of Psychiatry and Clinical Neuroscience.

[9]  G. Tsai,et al.  Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. , 2010, Current pharmaceutical design.

[10]  Norio Miyaura,et al.  Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .

[11]  C. Lindsley,et al.  Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. , 2006, Current topics in medicinal chemistry.

[12]  O. Hucke,et al.  Revealing Atropisomer Axial Chirality in Drug Discovery , 2011, ChemMedChem.

[13]  S. LaPlante,et al.  The challenge of atropisomerism in drug discovery. , 2009, Angewandte Chemie.

[14]  X. Tang,et al.  Huperzine A, a novel promising acetylcholinesterase inhibitor , 1996, Neuroreport.

[15]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[16]  Synthesis and biological evaluation of (4H-1,2,4-triazol-4-yl)isoquinoline derivatives as selective glycine transporter 1 inhibitors. , 2012, Bioorganic & medicinal chemistry.

[17]  P. Mallorga,et al.  The Glycine Transporter Type 1 Inhibitor N-[3-(4′-Fluorophenyl)-3-(4′-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior , 2003, The Journal of Neuroscience.

[18]  J. Gomeza,et al.  Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells. , 1995, Biochimica et biophysica acta.

[19]  P. Mátyus,et al.  Glycine transporter type-1 and its inhibitors. , 2006, Current medicinal chemistry.

[20]  S. Bröer,et al.  Neutral amino acid transport in epithelial cells and its malfunction in Hartnup disorder. , 2005, Biochemical Society transactions.

[21]  V. Ognyanov,et al.  ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. , 2001, Molecular pharmacology.

[22]  B. Slusher,et al.  Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice , 2006, Journal of Neural Transmission / General Section JNT.

[23]  M. Sarter,et al.  Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist β-carbolines , 2004, Psychopharmacology.

[24]  P. Carlsen,et al.  Synthesis of unsymmetrically substituted 4H-1,2,4-triazoles , 1994 .

[25]  O. Hucke,et al.  Assessing atropisomer axial chirality in drug discovery and development. , 2011, Journal of medicinal chemistry.

[26]  C. Sur,et al.  Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. , 2007, Current drug targets.

[27]  C. Sur,et al.  Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. , 2010, Current topics in medicinal chemistry.

[28]  R. Depoortère,et al.  Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic , 2005, Neuropsychopharmacology.

[29]  Y. Tanigawara,et al.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.

[30]  Katsuya Harada,et al.  A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. , 2012, European journal of pharmacology.

[31]  I. Weiner,et al.  Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia , 2005, Psychopharmacology.

[32]  A. Arnsten,et al.  Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  Alexander Alanine,et al.  Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. , 2010, Journal of medicinal chemistry.

[34]  R. McGuire,et al.  The first potent and selective inhibitors of the glycine transporter type 2. , 2001, Journal of medicinal chemistry.

[35]  B. Platt,et al.  Glutamate receptor function in learning and memory , 2003, Behavioural Brain Research.

[36]  S. Iversen,et al.  Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent gamma-butyrolactone-like sedative. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. D’Esposito,et al.  Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control , 2011, Biological Psychiatry.